Antigenics CEO to Present at Bear Stearns Healthcare Conference

Business Wire, Sept 12, 2005

NEW YORK -- Antigenics Inc. (NASDAQ: AGEN) announced today that Garo H Armen, PhD, the company's chairman and CEO, will give a presentation at the Bear Stearns 18th Annual Healthcare Conference at the Grand Hyatt Hotel in New York at 2:30 p.m. EDT on Tuesday, September 13, 2005. Dr. Armen will provide an overview of the company and an update on its clinical programs.

Antigenics is working to develop personalized immunotherapeutics and revolutionary treatments for cancers and infectious diseases. The company's lead product candidate is Oncophage(R) (HSPPC-96), a late-stage, personalized cancer vaccine being evaluated in several indications, including renal cell carcinoma and metastatic melanoma. Antigenics' portfolio of investigational products also includes AG-858 (HSPPC-70), a personalized cancer vaccine in Phase 2 development; two Phase 2 liposomal cancer treatments, Aroplatin(TM) and ATRA-IV; and AG-702/AG-707, a Phase 1 genital herpes program.